NCT03492125

A Study Of The Selective PKC-β Inhibitor MS- 553

A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: MingSight Pharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma
• Aggressive Lymphoma

Interventions

Type	Name	Description
DRUG	MS-553	Oral, multiple dose levels
DRUG	MS-553	Oral recommended phase 2 dose of MS-553
DRUG	acalabrutinib	Oral
DRUG	venetoclax	Oral
DRUG	Rituximab	IV
DRUG	obinutuzumab	IV

Timeline

• Start date: 2018-05-25
• Primary completion: 2023-11-28
• Completion: 2023-11-28
• First posted: 2018-04-10
• Last updated: 2025-04-10
• Results posted: 2025-04-10

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study